US basedUS hosted
Desks
$2 / month

Comment and reply across TML.

Start or manage membership

Most pulsed

Advertisement Sinscents Bad Intentions. Great Candles.

Latest from other desks

tml.the modern leap
Health / Public Health

FDA Puts NAION Eye Warning on Every GLP-1 Label

The Food and Drug Administration issued a Drug Safety Communication on November 9, 2026, requiring every GLP-1 receptor agonist, from Ozempic and Wegovy to Mounjaro and Zepbound, to carry a warning about NAION, a rare optic nerve condition that causes sudden vision loss in one eye. The agency's trial meta-analysis found 15 probable cases across 134,253 patients, and it describes a potential risk, not a proven cause.

An optometrist examining a patient's eye (archive). Photo: Kwameghana, CC BY-SA 4.0, via Wikimedia Commons.
Summary

A warning on every GLP-1 label doesn't tell patients to stop. It tells them the one symptom they shouldn't wait on: sudden vision loss in one eye is a same-day emergency, and now every prescriber has to say so.

Tap a passage. React to the part that matters.

The Food and Drug Administration is requiring every maker of a GLP-1 receptor agonist to add a warning about non-arteritic anterior ischemic optic neuropathy, known as NAION, to the Warnings and Precautions section of its label. The agency issued the requirement in a Drug Safety Communication on November 9, 2026, concluding there's a potential increased risk of the rare eye condition in patients taking the drugs. NAION is a sudden, usually painless loss of vision in one eye, caused when blood flow to the front of the optic nerve drops.

The breadth is the point. Most public attention has centered on semaglutide, sold as Ozempic, Rybelsus and Wegovy by Novo Nordisk, but the FDA applied the change to the whole class: tirzepatide (Mounjaro and Zepbound, from Eli Lilly), liraglutide (Victoza and Saxenda), dulaglutide (Trulicity), exenatide and the oral agent orforglipron (Foundayo), which was approved earlier this year. The agency says NAION cases have been reported in postmarketing surveillance for every GLP-1 drug currently on the market.

The FDA was candid that no single dataset settled the question. Its review drew on six streams of evidence. The largest was a meta-analysis of 126 randomized controlled trials covering 134,253 patients and 288,879 person-years of exposure, which found 15 probable NAION events: 10 in patients on a GLP-1 drug, 5 on placebo and none in patients on other glucose-lowering drugs. That's about 6.4 events per 100,000 person-years on GLP-1 drugs against 3.8 on placebo or comparators. The agency also analyzed its Sentinel system data for adults with type 2 diabetes who started a GLP-1 drug, an SGLT-2 inhibitor or a DPP-4 inhibitor between 2019 and 2024.

Scale matters here, because NAION is rare with or without these drugs. The FDA puts the background rate at 2.3 to 10.2 cases per 100,000 people per year in adults over 50. The agency describes a potential risk, not a proven cause: it says the underlying mechanism isn't completely understood and animal data identified no mechanism. Europe reached a narrower version of the same conclusion earlier, when the European Medicines Agency's safety committee classed NAION as a very rare side effect of semaglutide in 2025, affecting up to 1 in 10,000 people taking it for at least a year.

The practical instruction is aimed at the exam room. The FDA advises prescribers to tell patients to report any sudden, painless loss of vision, a visual field deficit or another visual disturbance in one eye immediately, and to refer anyone with suspected NAION promptly to an ophthalmologist. Clinicians are also told to consider stopping the drug in a patient who develops NAION unless the benefits clearly outweigh the risk. The communication doesn't tell patients to stop their medication on their own, and it isn't a recall or a restriction on who can take the drugs.

What changes for the millions of people on these medicines is mostly a label and a conversation. Updated labels will appear as each company revises its own, and the warning gives prescribers a documented reason to ask about vision at follow-up visits. The drugs' benefits in diabetes and weight management aren't in dispute in the communication. The FDA's judgment is narrower: a rare, serious event that patients can't recognize unless someone names it in advance now gets named on every label in the class.

The conversation

A little more perspective.

Reading is free. Verified members can comment and reply for $2 a month.

The conversation.

Loading comments…

Keep your curiosity going.

Some links here are affiliate links. If you buy through one, we might make a commission — it never changes what you pay. As an Amazon Associate I earn from qualifying purchases.